RenovoRx, a life sciences company, announced that its CEO and CFO will present the company's third quarter 2026 financial results and business progress at the Canaccord Genuity MedTech Forum on November 11, 2026. They will highlight the commercial growth and increased adoption of RenovoRx's FDA-cleared RenovoCath device and its Trans-Arterial Micro-Perfusion (TAMP) platform, used for targeted drug delivery in cancer treatment. The company reported $1.1 million in RenovoCath sales in 2025 and record quarterly revenue of $909,000 in Q2 2026. RenovoRx is also advancing its drug-device combination therapy in a Phase III trial, with topline data expected in late 2027.
RenovoRx's upcoming presentation at the Canaccord Genuity MedTech Forum coincides with a Health sector where 42 of 150 US stocks rose and 97 fell on Pluang. For readers following Health stocks, here is Pluang's market snapshot as of Oct 28, 2026 19:11 WIB: GSK traded at USD 48.27 with a 1-day change of -5.24% and a typical hold time of 94 days, showing 100% sell order activity; Avantor Inc. (AVTR) was at USD 16.49, down 3.74%, with an 11-day hold time; Dyne Therapeutics (DYN) stood at USD 16.42, down 3.07%, with a 6-day hold time.
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
Circuit Mind secured $25 million in funding, including an $18.5 million Series A led by Norwest, to expand its AI platform that automates and optimizes electronic circuit board design. The platform helps companies reduce design time by up to 90%, cut...
Alvotech, a global biotech company specializing in biosimilars, will release its financial results for the first nine months of 2026 on November 11 after U.S. market close. A live webcast presentation is scheduled for November 12 at noon, where manag...
Sampo Oyj will publish its financial results for the first nine months of 2026 on November 4, 2026, at around 8:30 AM. Alongside the report, supplementary presentation materials will be available on their website. An investor conference call will be ...
